For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.

Outcome Health raises $500 million in financing round

Outcome Health raises $500 million in financing round

The deal highlights ongoing interest in the influential point-of-care market.

2017 Pharma Report: All the data in one place

2017 Pharma Report: All the data in one place

Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Otsuka, Proteus refile their sensor-enabled drug

Otsuka, Proteus refile their sensor-enabled drug

The chip-in-a-pill combines antipsychotic Abilify with an ingestible sensor made by Proteus.

Back at Dendreon, Caggiano takes on Provenge's comeback

Back at Dendreon, Caggiano takes on Provenge's comeback

Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.

Five things for pharma marketers to know: Monday, May 8, 2017

Five things for pharma marketers to know: Monday, May 8, 2017

Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions

Value-based care requires innovators to challenge the status quo

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

4 reasons why patients don't fill their prescriptions

4 reasons why patients don't fill their prescriptions

Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.

Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.